As you seem to go into a tizzy regardless of what I say, I would like to try an experiment - I'll say something very negative about something and we'll wait 24 hours and see if you remain calm or or foam at the mouth. OK - here goes..."As a musical instrument for rock and roll, accordians suck".
2. Thank you for defining "respond" in relation to my post #900 where I asked what "respnd" meant when Dr. Amy Patrick of Agouron claimed that 39% of patients who have failed other p.i. inhibitors "responded" tho p.i. therapy with Viracept.
3. Given the response with Viracept when the other p.i. therapy failed plus the notion of being able to start with Viracept and then switch when that stopped working would seem to indicate that the mutation difference for Viracept is pretty impressive, yes? I'd say that if Viracept and Crix were pretty equal in "effectiveness" in a naive patient, the clear chice would have to be Viracept, yes?
4. As someone with the potential to actually buy lots of AGPH, I just want a little more convincing, though. Please state how important the Amy Patrick stuff on mutations and the PI switching ability is to a) the basis for using Viracept as the initial PI and b) the investment case for AGPH.
5. It should seem obvious that all I care about is making money, right? If true, then by answering these simple questions, you can convince me and others who may be sitting on the fence regarding whether to buy AGPH to actually go ahead and do it. Also, you could very well convince short sellers that they are wrong and they will cover, the stock will go up and you will make money faster that you even had hoped.
6. That is is all, and I am not a pizza delivery man, I am the easter bunny.
7. Lighten up, my man! |
